KINETA_web_hp_redpoint
KINETA_web_hp_redpoint

Developing Next-Generation Immunotherapies for Cancer Patients

The introduction of new checkpoint inhibitor (CPI) immunotherapies into the clinic has significantly improved the prognosis for many cancer patients over the last decade, but the overall response rates remain relatively low in all tumor types. There remains a significant unmet need to improve overall and long-term survival for cancer patients. New innovation and enhancements to the currently available therapies are urgently needed to address the treatment gaps.

Next-generation cancer treatments require:

  • Improving survival for CPI non-responders (70%-80%)

  • Reprogramming the immune system to attack cancer

  • Integrating linnate and adaptive immune responses 

KINETA_web_hp_redpoint

Addressing cancer immune resistance

Kineta is building next-generation immunotherapies to address the major challenges with current cancer treatments.  We aim to improve outcomes for cancer patients by solving the problems of cancer resistance.  Our novel drug programs are focused on addressing and correcting immuno-suppression, exhausted T-cells and poor tumor immunogenicity.

KINETA_web_hp_redpoint

Kineta Pipeline

Kineta’s mission is to develop next-generation immunotherapies that transform patients’ lives. Kineta is focused on developing fully human antibodies that address the mechanisms of cancer immune resistance.

Drug Program

Discovery

Pre-clinical

Phase 1

Phase 2

Phase 3

Anticipated Milestones

Indications:
Advanced solid tumors
NSCLC, CRC, OC

KVA1212343%

4Q 2022:  IND Approval & Initiate Phase 1
2Q 2023:  Initiate pembrolizumab combo cohort
Q4 2023:  Initial Phase 1 data readout

Indications:
Advanced solid tumors

15%

1H 2024:  IND filing
1H 2024:  Start Phase 1 clinical study